Neuberger Berman Group LLC bought a new stake in AngioDynamics, Inc. (NASDAQ:ANGO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 19,193 shares of the medical instruments supplier’s stock, valued at approximately $311,000. Neuberger Berman Group LLC owned approximately 0.05% of AngioDynamics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. State of Alaska Department of Revenue raised its position in shares of AngioDynamics by 91.7% in the 2nd quarter. State of Alaska Department of Revenue now owns 6,768 shares of the medical instruments supplier’s stock valued at $109,000 after purchasing an additional 3,238 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its position in shares of AngioDynamics by 77.5% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 7,100 shares of the medical instruments supplier’s stock valued at $123,000 after purchasing an additional 3,100 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its position in shares of AngioDynamics by 3.0% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 7,200 shares of the medical instruments supplier’s stock valued at $125,000 after purchasing an additional 210 shares in the last quarter. Mason Street Advisors LLC raised its position in shares of AngioDynamics by 8.5% in the 1st quarter. Mason Street Advisors LLC now owns 7,470 shares of the medical instruments supplier’s stock valued at $130,000 after purchasing an additional 584 shares in the last quarter. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of AngioDynamics in the 1st quarter valued at approximately $175,000. 95.71% of the stock is currently owned by institutional investors.

AngioDynamics, Inc. (ANGO) opened at 17.86 on Monday. AngioDynamics, Inc. has a 12 month low of $14.80 and a 12 month high of $18.35. The firm has a market capitalization of $653.32 million, a price-to-earnings ratio of 130.36 and a beta of 1.14. The firm has a 50 day moving average price of $17.00 and a 200-day moving average price of $16.31.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.03. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The firm had revenue of $86.90 million during the quarter, compared to the consensus estimate of $90.72 million. During the same quarter in the prior year, the company earned $0.19 EPS. The firm’s revenue for the quarter was down 7.0% compared to the same quarter last year. On average, equities analysts forecast that AngioDynamics, Inc. will post $0.67 EPS for the current year.

In other news, CEO James C. Clemmer acquired 20,000 shares of AngioDynamics stock in a transaction on Thursday, July 20th. The stock was bought at an average price of $15.64 per share, for a total transaction of $312,800.00. Following the transaction, the chief executive officer now owns 86,683 shares of the company’s stock, valued at $1,355,722.12. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO James C. Clemmer acquired 5,000 shares of AngioDynamics stock in a transaction on Friday, July 21st. The stock was purchased at an average price of $15.79 per share, with a total value of $78,950.00. Following the transaction, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. Insiders acquired a total of 25,316 shares of company stock valued at $396,806 in the last quarter. Corporate insiders own 1.80% of the company’s stock.

ANGO has been the topic of a number of recent analyst reports. Barclays PLC cut their target price on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 19th. KeyCorp reaffirmed a “hold” rating on shares of AngioDynamics in a research report on Friday, August 25th. BidaskClub raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Finally, Canaccord Genuity reaffirmed a “hold” rating and issued a $16.50 target price on shares of AngioDynamics in a research report on Wednesday, May 31st. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $18.60.

ILLEGAL ACTIVITY NOTICE: “Neuberger Berman Group LLC Invests $311,000 in AngioDynamics, Inc. (ANGO)” was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/09/25/neuberger-berman-group-llc-invests-311000-in-angiodynamics-inc-ango.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.